

June 1, 2020

John J. Howard, MD
Administrator
World Trade Center Health Program
National Institute for Occupational Safety and Health
Centers for Disease Control and Prevention
Via Regulations.gov submission

Re: NIOSH Docket #334, CDC-2020-0035
World Trade Center Health Program Research Agenda

Dear Dr. Howard:

On behalf of the American Thoracic Society (ATS), thank you for the opportunity to provide comments on the 2021 World Trade Center Health Program Research Agenda. The ATS looks forward to working with the National Institute for Occupational Safety and Health (NIOSH) to further develop and implement this plan and provide expert peer review of grant applications. We have the following comments and recommendations:

World Trade Center (WTC) rescue and recovery workers and survivors have a high burden of chronic health conditions (CHC) associated with WTC-exposures.¹ Such CHC include upper and lower respiratory conditions (asthma, COPD, chronic rhino-sinusitis), GERD, mental health disease such as post-traumatic stress syndrome (PTSD), cardiovascular disease/risk factors and neurocognitive decline, and each of them is associated with reduced quality of life and sleep quality.^{2,3}

Most recently, a high risk for cancer incidence, particularly of the head and neck, thyroid and prostate has been consistently reported across several WTC cohorts.⁴ Because asbestos was used for insulation when the WTC towers were built, there is also concern that anyone within a 1.5 mile radius of the WTC was at risk for asbestos exposure. An increase in reported cases of mesothelioma is thus expected to emerge in the near future, given twenty to fifty-year latency. Furthermore, cardiovascular disease and risk factors have been identified as WTC-associated CHC. Specifically, classic cardiovascular risk factors such as metabolic syndrome have been identified as risks of WTC-Lung Injury and WTC-Airway Hyperreactivity.⁵⁻¹³

The known progression of CHC in the WTC cohort and increased cancer incidence decades after the original exposure raises concern for unrecognized cardiovascular risk, sleep disturbance and

JUAN C. CELEDÓN, MD, DrPH, ATSF
President

LYNN M. SCHNAPP, MD, ATSF
President-Elect

JAMES M. BECK, MD, ATSF
Immediate Past President

GREGORY P. DOWNEY, MD, ATSF
Vice President

M. PATRICIA RIVERA, MD, ATSF
Secretary-Treasurer

KAREN J. COLLISHAW, MPP, CAE
Executive Director



We help the world breathe®
PULMONARY • CRITICAL CARE • SLEEP

1150 18th Street, N.W., Suite 300
Washington, D.C. 20036 U.S.
T. 202-296-9770 F. 202-296-9776 | thoracic.org

 **ATS 2020** | VIRTUAL
AUGUST 2020

disease. Metabolic syndrome affects at least 30 % of the WTC-exposed population.^{7,11-13} There is recent literature that metabolically active pathways are relevant to the development of WTC-lung disease in murine models and that inhibition of these pathways are protective.¹⁴⁻¹⁶

Notably, the prevalence of obstructive sleep apnea (OSA), through questionnaire or objective testing, is as high as 60-80%, much higher than observed in other epidemiologic cohorts with similar characteristics, and in middle-aged general, non-WTC populations.¹⁷⁻²¹ In turn, untreated OSA is a well-established risk for cardiovascular, cerebrovascular and neurocognitive/neurodegenerative morbidity and mortality.^{22,23 24,25} Additionally, in patients with PTSD, coexistent sleep disturbance/insomnia and OSA worsen PTSD symptoms, quality of life and adversely impact response to PTSD treatment.²⁶

Research Recommendations

The WTC cohort is an appropriate group for research inquiries into the aforementioned interactions. Given the specific morbidities and risks of this cohort, the ATS recommends that the World Trade Center Health Program research agenda include the following research priorities:

1. Continued research on pulmonary diseases such as asthma/COPD, and lung cancer, with exploration of other areas such as interstitial lung disease, granulomatous lung disease, asbestosis, and mesothelioma risk
2. Studying the effects of PTSD on both airway disease and sleep disorders
3. Continued assessment of the association of 9/11 exposure to morbidities such as multisystem or autoimmune, cardiovascular and neurologic diseases
4. Further assessing changes in the health of children that were exposed on 9/11
5. Characterizing established WTC-related diseases and comorbidities to identify phenotypes, epigenetic mechanisms, and omics biomarkers
6. Determining cardiopulmonary risk phenotype in WTC- exposed populations (e.g., omic and clinical biomarkers)
7. Characterize pathways involved in WTC associated cardiopulmonary disease; further develop murine models of WTC-Associated CHC such as lung injury, airway hyperreactivity
8. Study of phenotypes/mechanisms of sleep disturbance insomnia and OSA in this cohort, and their roles in predicting incidence of related disease (cancer, mental health issues, cancer), adherence and response to treatment modalities for sleep disturbance and OSA

9. Determine how WTC-exposure and metabolic derangement interact to potentiate disease development of WTC associated lung and vascular disease
10. Exploration of the role of WTC exposures in increasing the risk for upper airway cancers

Again, we thank you for the opportunity to provide feedback. We look forward to further assisting the WTC Program with specific research priorities and any other information. Please contact Nuala S. Moore, Director of Government Relations with any questions or for more information at Nmoore@thoracic.org.

Sincerely,



Juan C. Celedón, M.D., DrPH, ATSF
President
American Thoracic Society

JUAN C. CELEDÓN, MD, DrPH, ATSF
President

LYNN M. SCHNAPP, MD, ATSF
President-Elect

JAMES M. BECK, MD, ATSF
Immediate Past President

GREGORY P. DOWNEY, MD, ATSF
Vice President

M. PATRICIA RIVERA, MD, ATSF
Secretary-Treasurer

KAREN J. COLLISHAW, MPP, CAE
Executive Director



We help the world breathe®
PULMONARY • CRITICAL CARE • SLEEP

1150 18th Street, N.W., Suite 300
Washington, D.C. 20036 U.S.
T. 202-296-9770 F. 202-296-9776 | thoracic.org

 **ATS 2020** | VIRTUAL
AUGUST 2020

REFERENCES:

1. Wisnivesky JP, Teitelbaum SL, Todd AC, et al. Persistence of multiple illnesses in World Trade Center rescue and recovery workers: a cohort study. *Lancet*. 2011;378(9794):888-897.
2. Clouston S, Pietrzak RH, Kotov R, et al. Traumatic exposures, posttraumatic stress disorder, and cognitive functioning in World Trade Center responders. *Alzheimers Dement (N Y)*. 2017;3(4):593-602.
3. Clouston SA, Kotov R, Pietrzak RH, et al. Cognitive impairment among World Trade Center responders: Long-term implications of re-experiencing the 9/11 terrorist attacks. *Alzheimers Dement (Amst)*. 2016;4:67-75.
4. Boffetta P, Zeig-Owens R, Wallenstein S, et al. Cancer in World Trade Center responders: Findings from multiple cohorts and options for future study. *Am J Ind Med*. 2016;59(2):96-105.
5. Weiden MD, Naveed B, Kwon S, et al. Cardiovascular biomarkers predict susceptibility to lung injury in World Trade Center dust-exposed firefighters. *Eur Respir J*. 2013;41(5):1023-1030.
6. Nolan A, Naveed B, Comfort AL, et al. Inflammatory biomarkers predict airflow obstruction after exposure to World Trade Center dust. *Chest*. 2012;142(2):412-418.
7. Naveed B, Weiden MD, Kwon S, et al. Metabolic syndrome biomarkers predict lung function impairment: a nested case-control study. *Am J Respir Crit Care Med*. 2012;185(4):392-399.
8. Tsukiji J, Cho SJ, Echevarria GC, et al. Lysophosphatidic acid and apolipoprotein A1 predict increased risk of developing World Trade Center-lung injury: a nested case-control study. *Biomarkers*. 2014;19(2):159-165.
9. O'Byrne PM, Inman MD. Airway hyperresponsiveness. *Chest*. 2003;123(3 Suppl):411S-416S.
10. Pellegrino R, Viegi G, Brusasco V, et al. Interpretative strategies for lung function tests. *Eur Respir J*. 2005;26(5):948-968.
11. Webber MP, Yip J, Zeig-Owens R, et al. Post-9/11 sarcoidosis in WTC-exposed firefighters and emergency medical service workers. *Respir Med*. 2017;132:232-237.
12. Kwon S, Crowley G, Caraher EJ, et al. Validation of Predictive Metabolic Syndrome Biomarkers of World Trade Center Lung Injury: A 16-Year Longitudinal Study. *Chest*. 2019;156(3):486-496.
13. Kwon S, Crowley G, Mikhail M, et al. Metabolic Syndrome Biomarkers of World Trade Center Airway Hyperreactivity: A 16-Year Prospective Cohort Study. *Int J Env Res Pub He*. 2019;16(9):1486.
14. Caraher EJ, Kwon S, Haider SH, et al. Receptor for advanced glycation end-products and World Trade Center particulate induced lung function loss: A case-cohort study and murine model of acute particulate exposure. *Plos One*. 2017;12(9).
15. Haider SH, Veerappan A, Crowley G, et al. MultiOMICs of WTC-Particulate Induced Persistent Airway Hyperreactivity: Role of Receptor for Advanced Glycation End Products. *Am J Respir Cell Mol Biol*. 2020.
16. Veerappan A, Oskuei A, Crowley G, et al. World Trade Center-Cardiorespiratory and Vascular Dysfunction: Assessing the Phenotype and Metabolome of a Murine Particulate Matter Exposure Model. *Sci Rep*. 2020;10(1):3130.

17. de la Hoz RE, Aurora RN, Landsbergis P, Bienenfeld LA, Afilaka AA, Herbert R. Snoring and obstructive sleep apnea among former World Trade Center rescue workers and volunteers. *J Occup Environ Med.* 2010;52(1):29-32.
18. de la Hoz RE, Mallea JM, Kramer SJ, Bienenfeld LA, Wisnivesky JP, Aurora RN. Polysomnographic Diagnoses Among Former World Trade Center Rescue Workers and Volunteers. *Archives of Environmental & Occupational Health.* 2012;67(4):239-242.
19. Webber M, Lee R, Soo J, et al. Prevalence and incidence of high risk for obstructive sleep apnea in World Trade Center-exposed rescue/recovery workers. *Sleep and Breathing.* 2010:1-12.
20. Ayappa I, Chen Y, Bagchi N, et al. The Association between Health Conditions in World Trade Center Responders and Sleep-Related Quality of Life and Sleep Complaints. *Int J Environ Res Public Health.* 2019;16(7).
21. Sunderram J, Weintraub M, Black K, et al. Chronic Rhinosinusitis Is an Independent Risk Factor for OSA in World Trade Center Responders. *Chest.* 2019;155(2):375-383.
22. Marin JM, Carrizo SJ, Vicente E, Agusti AGN. Long-term cardiovascular outcomes in men with obstructive sleep apnoea-hypopnoea with or without treatment with continuous positive airway pressure: an observational study. *Lancet.* 2005;365(9464):1046-1053.
23. Peppard PE, Young T, Palta M, Skatrud J. Prospective study of the association between sleep-disordered breathing and hypertension. *N Engl J Med.* 2000;342(19):1378-1384.
24. Bubu OM, Pirraglia E, Andrade AG, et al. Obstructive sleep apnea and longitudinal Alzheimer's disease biomarker changes. *Sleep.* 2019;42(6).
25. Cedernaes J, Osorio RS, Varga AW, Kam K, Schioth HB, Benedict C. Candidate mechanisms underlying the association between sleep-wake disruptions and Alzheimer's disease. *Sleep Med Rev.* 2017;31:102-111.
26. El-Solh AA, Riaz U, Roberts J. Sleep Disorders in Patients With Posttraumatic Stress Disorder. *Chest.* 2018;154(2):427-439.
27. El-Solh AA, Adamo D, Kufel T. Comorbid insomnia and sleep apnea in Veterans with post-traumatic stress disorder. *Sleep Breath.* 2018;22(1):23-31.
28. Kawada T. Obstructive sleep-disordered breathing and cancer: mechanism of association. *Sleep Breath.* 2019;23(4):1357.
29. Owens RL, Gold KA, Gozal D, et al. Sleep and Breathing ... and Cancer? *Cancer Prev Res (Phila).* 2016;9(11):821-827.

JUAN C. CELEDÓN, MD, DrPH, ATSF
President

LYNN M. SCHNAPP, MD, ATSF
President-Elect

JAMES M. BECK, MD, ATSF
Immediate Past President

GREGORY P. DOWNEY, MD, ATSF
Vice President

M. PATRICIA RIVERA, MD, ATSF
Secretary-Treasurer

KAREN J. COLLISHAW, MPP, CAE
Executive Director



We help the world breathe®
PULMONARY • CRITICAL CARE • SLEEP

1150 18th Street, N.W., Suite 300
Washington, D.C. 20036 U.S.
T. 202-296-9770 F. 202-296-9776 | thoracic.org

 **ATS 2020** | VIRTUAL
AUGUST 2020